On-Demand Content | Virtual Event
Carve-outs, estoppel, restrictions on venue, and ANDA litigation remain some of the hottest contested issues under Paragraph IV of the Hatch-Waxman Act. Via Momentum’s fully interactive platform, join us as our conference faculty of esteemed judges, leading in-house counsel and experienced practitioners provide you with the tactics, tools, strategies and insight you need when litigating Paragraph IV cases.
SPEAKER HIGHLIGHTS
Honorable Jacqueline Wright Bonilla
Deputy Chief Administrative Patent Judge, Patent Trial and Appeal Board
USPTO
Honorable Michelle N. Ankenbrand
Lead Administrative Patent Judge
USPTO
Jeff Bank
Partner
WILSON SONSINI GOODRICH & ROSATI P.C.
Honorable Jacqueline Wright Bonilla
Deputy Chief Administrative Patent Judge, Patent Trial and Appeal Board
USPTO
Arlene Chow
Partner
LATHAM & WATKINS LLP
Ryan Coletti
Vice President, Intellectual Property and Litigation
SHIONOGI INC.
Betsy Flanagan
Principal
FISH & RICHARDSON P.C.
John Haberman
Senior Director, IP
SAREPTA THERAPEUTICS
Jake M. Holdreith
Partner, Member of the Executive Board
ROBINS KAPLAN LLP
Kurt Karst
Director
HYMAN, PHELPS & MCNAMARA, P.C.
John Kirkland
Senior Director of IP and Litigation
ALKERMES
Brian Malkin
Partner
MCDERMOTT WILL & EMERY LLP
Donna Meuth
Associate General Counsel Intellectual Property
EISAI
Paul Molino
Partner
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
Kevin E. Noonan
Partner
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
Irena Royzman
Partner & Head of Life Sciences
KRAMER LEVIN NAFTALIS & FRANKEL LLP
Honorable Kristi Rupert Sawert
Administrative Patent Judge
USPTO
Sanya Sukduang
Partner
COOLEY LLP
Jeanna Wacker
Partner
KIRKLAND & ELLIS P.C.
Bruce Wexler
Partner
PAUL HASTINGS LLP
Ha Kung Wong
Partner
VENABLE LLP
Top Reasons to Purchase
- Obtain the thoughts of Federal Circuit and PTAB Judges regarding to best practices when arguing a case related to pharmaceutical IP
- Put the outcomes of “GSK v. Teva” and “Minerva Surgical v Hologic Inc” into use as you prepare for upcoming Paragraph IV litigation
- Strengthen your abilities to protect company intellectual property overseas by examining current international regulations and court rulings
- Further understand how President Biden’s potential waiver in the fight against COVID-19 may affect the IP rights of pharmaceuticals and biologics going forward
- Network with leading Paragraph IV experts to ready yourself for future litigation
Who Should Purchase
Professionals from Pharmaceutical and Medical Device Companies with Titles Including:
- Associate General Counsel, Litigation
- Associate General Counsel, IP
- Patent Counsel
- Senior Legal Counsel
- Vice-President, Intellectual Property
- Director, Intellectual Property
- General Counsel
- Head of Intellectual Property
SILVER SPONSOR
Supporting Sponsor
Media Partner
On-Demand Content
$195
Continuing Legal Education credits (CLE) offered at this event. For more information, click here
